Perbak Capital Partners »

Denali Therapeutics shares owned by Perbak Capital Partners

Quarter-by-quarter ownership of Denali Therapeutics (DNLI) shares owned by Perbak Capital Partners from 13F filings

Historical chart of Perbak Capital Partners investment in Denali Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Denali Therapeutics held by Perbak Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Denali Therapeutics by Perbak Capital Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $208k 13k 16.51

More positions owned by Perbak Capital Partners

Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Select Sector Spdr Tr State Street Ind (XLI)
Vaneck Etf Trust Oil Services Etf (OIH)
Spdr Series Trust State Street Spd (KIE)
Select Sector Spdr Tr State Street Con (XLP)
Ishares Tr Ishares Semicdtr (SOXX)
Spdr Series Trust State Street Spd (XRT)
Waters Corporation (WAT)
RBC Bearings Incorporated (RBC)
Qiagen Nv Com Shs
Illumina (ILMN)
Spdr Series Trust State Street Spd (XHB)
Danaher Corporation (DHR)
Mettler-Toledo International (MTD)

View all positions for Perbak Capital Partners

Top funds holding Denali Therapeutics

Vanguard Group
BlackRock
Baillie Gifford & Co
T. Rowe Price Investment Management
FMR
State Street Corporation
Temasek Holdings
Norges Bank Investment Management
Ubs Global Asset Management Americas
Goldman Sachs Group
Baker Bros. Advisors
Capital Research Global Investors
Alliancebernstein
Geode Capital Management
Holocene Advisors

View all funds holding Denali Therapeutics